clinical trial · NCT04325217
Post-marketing Surveillance on Long Term Use of Ofev Capsules in Systemic Scleroderma Associated Interstitial Lung Disease (SSc-ILD) in Japan
Boehringer Ingelheim·—·active not recruiting·n = 586
Lung Diseases, InterstitialNintedanib
brief summary
The primary objective is to confirm the incidence of adverse drug reactions (focus on gastrointestinal symptoms including diarrhoea and nausea) to Ofev Capsules seen in clinical trials with real world data generated in patients with SSc-ILD.
started
May 27, 2020
primary completion
Jun 30, 2026
completion
Jun 30, 2026
last updated
Mar 17, 2026
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol